Research programme: protein kinase inhibitors - Locus Pharmaceuticals/Ono Pharmaceutical

Drug Profile

Research programme: protein kinase inhibitors - Locus Pharmaceuticals/Ono Pharmaceutical

Latest Information Update: 09 Feb 2011

Price : $50

At a glance

  • Originator Locus Pharmaceuticals; Ono Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 09 Feb 2011 This research programme is still in active development
  • 21 Jan 2010 This research programme is still in active development
  • 07 Nov 2007 Locus Pharmaceuticals and Ono Pharmaceutical enter into a second research agreement for the development of targeted kinase inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top